Skip to content

Effect of Jiedu Quyu Ziyin Formula on the Clinical Efficacy of Sjogren's Syndrome, Immune Inflammatory Indexes and Depression

Effect of Jiedu Quyu Ziyin Formula on the Clinical Efficacy of Sjogren's Syndrome, Immune Inflammatory Indexes and Depression

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072206
Enrollment
Unknown
Registered
2023-06-06
Start date
2023-06-24
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sjogren's Syndrome

Interventions

experimental group:jie-du-qu-yu-zi-yin fang with HCQ
control1:HCQ
control1:Iguratimod

Sponsors

Huzhou Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All SS should conform to the international classification (diagnosis) standard of Sjogren's syndrome in 2016, and the syndrome differentiation of TCM should be yin deficiency, heat toxin and blood stasis syndrome

Exclusion criteria

Exclusion criteria: ? Those accompanied with serious heart, lung, liver, kidney, endocrine, metabolic, blood, cerebrovascular and other diseases are excluded; ? The patients with other serious autoimmune diseases are excluded; ? Those accompanied with solid tumors and hematological tumors are excluded; (4) SS gets worse or has serious complications, except for those requiring unconventional treatment; (5) Those with HAMD score greater than 24, who need to take antidepressants or have negative risks, and those with other serious mental diseases are excluded.

Design outcomes

Primary

MeasureTime frame
ESSDAI;

Secondary

MeasureTime frame
ESR;CRP;IL6;TNFa;

Countries

China

Contacts

Public ContactYang xiaobing

Huzhou Third People's Hospital

xzj575@163.com+86 137 5713 2498

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026